Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 69, Number 13, September 25, 2007
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schiff, D.
Right arrow Articles by Giannini, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schiff, D.
Right arrow Articles by Giannini, C.
Related Collections
Right arrow Primary brain tumor
Right arrow Chemotherapy-tumor
Right arrow Radiation therapy-tumor
Right arrow Surgical therapy-tumor
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
Right arrow Clinical trials Methodology/study design
NEUROLOGY 2007;69:1366-1373
© 2007 American Academy of Neurology
Views & Reviews

Outcome in adult low-grade glioma

The impact of prognostic factors and treatment

David Schiff, MD, Paul D. Brown, MD and Caterina Giannini, MD

From the Neuro-Oncology Center (D.S.), University of Virginia Health Sciences Center, Charlottesville, and Departments of Radiation Oncology (P.D.B.) and Laboratory Medicine and Pathology (C.G.), Mayo Clinic College of Medicine, Rochester, MN.

Address correspondence and reprint requests to Dr. D. Schiff, Neuro-Oncology Center, University of Virginia Health Sciences Center, Box 800432, Charlottesville, VA 22908-0432 ds4jd{at}virginia.edu

Low-grade gliomas (LGGs) represent a vexing clinical problem. Some patients present with readily controllable seizures and will enjoy years of freedom from tumor progression without intervention, whereas others progress rapidly with eventual neurologic decompensation and death. Both radiation and chemotherapy are helpful to many patients, but the optimal timing and sequencing of these therapies remain unknown. Recent studies have informed our understanding of clinical, histologic, and molecular prognostic factors and help provide guidance as to which patients require early intervention and when observation is feasible or warranted. We review contemporary knowledge regarding prognostic factors, our current evidence-based understanding of the roles and timing of radiation and chemotherapy, and ongoing clinical trials that will further elucidate management of LGGs.

GLOSSARY: CCNU = lomustine; EORTC = European Organization for Research and Treatment of Cancer; FISH = fluorescence in situ hybridization; LGG = low-grade glioma; LOH = loss of heterozygosity; MGMT = O6-methylguanine-DNA methyltransferase; OS = overall survival; WHO = World Health Organization; PCV = procarbazine, CCNU, and vincristine; PFS = progression-free survival; QOL = quality of life; RT = radiation therapy.

Disclosure: Dr. Schiff has given lectures through the Schering-Plough Speaker’s Bureau and served as a consultant to Schering-Plough.

Received January 2, 2007. Accepted in final form March 22, 2007.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.